2 completed, 1 terminated. 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Medigene AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms MDG1011, Investigator Choice therapy - Safety, Tolerability | Phase 1 / Phase 2 | Terminated | Medigene AG | 9 | 2018-03-27 | 2023-02-15 |
| DC Vaccination for Post-remission Therapy in AML WT1/PRAME vaccination - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Medigene AG | 20 | 2015-03-01 | 2020-07-07 |
| Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Sinecatechins 10%, Placebo - Carcinoma, Basal Cell | Phase 2 / Phase 3 | Completed | Maastricht University Medical Center | 42 | 2014-11-01 | 2016-05-18 |
Carcinoma, Basal Cell (1) · Leukemia, Myeloid, Acute (1)
green tea extract polyphenone E (1)
Germany (1) · Netherlands (1) · Norway (1)
Nicole WJ Kelleners-Smeets, MD, PhD (1) · Simone Thomas, PD Dr. med. (1)